Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

Marketed Products in GI Carcinoid NETs, 2012 48Figure 26: Strategic Competitor Assessment of the Major Marketed Products in Pancreatic NETs, 2012 49Figure 27: Neuroendocrine Carcinoma Therapeutics Pipeline by Phase of Clinical Development, 2012 53Figure 28: Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Mechanism of Action, 2012 55Figure 29: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline, 2012 56Figure 30: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline – Description, 2012 57Figure 31:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Region/Country, 2012 62Figure 32:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012 63Figure 33:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012 64Figure 34:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Overall Sponsors, 2012 65Figure 35: Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Prominent Sponsors, 2012 66Figure 36:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012 67Figure 37:GI Carcinoids NETs Therapeutics – Implications for Future Market Competition, 2012 68Figure 38:Pancreatic NETs Therapeutics – Implications for Future Market Competition, 2012 69Figure 39:Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Company, 2012 70Figure 40- GlobalData Market Forecasting Model 83

Companies mentioned

Advanced Accelerator Applications S.A

Novartis AG

F. Hoffmann-La Roche

Ipsen SA

To order this report:Therapy Industry:
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp Biopharmaceutical,s ... ZMapp™ antibody therapeutic to fight the Ebola outbreak ... and time-consuming the production of pharmaceuticals can be, ... publisher said that while some may be taken ... compound, those with industry knowledge are well aware ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... Department of Food Science and Technology, , ... Abstract , Chromosomal ... compared to those of a standard laboratory karyotype. Qualitative analysis , ... wine strains are aneuploid , and two ...
... Contributed by Jacqueline Boultwood, Gail M. Abrahamson, and J.,S. ... Headington, Oxford,OX3 9DU, United Kingdom , ... Introduction , ... in a non-invasive manner. For,example, peripheral blood may be used as ...
, , , , back to top...
Cached Biology Technology:Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 2Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 3Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 4Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 5Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 6PFGE Analysis of Chromosomal DNA From a Single Hair Root 2
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... prairie around Alberta,s Drumheller area was once a lush ... inland sea, with loads of wetlands inhabited by dinosaurs, ... changed about 71-million-years ago, according to a new study ... at the University of Calgary. The researchers, calculations show ...
... least three servings of dairy daily are three times more ... a new University of Illinois study. "And only one ... recommended amount of dairy," said Margarita Teran-Garcia, a U of ... alarming finding means that three-fourths of the 18- to 25-year-old ...
... -- Kansas State University civil engineers are developing the ... it stronger. Their innovative ingredient: biofuel byproducts. "The ... a material to use in concrete as a partial ... civil engineering, Kabul, Afghanistan. "By using these materials we ...
Cached Biology News:Dinosaur-era climate change study suggests reasons for turtle disappearance 2College kids who don't drink milk could face serious consequences 2Researchers building stronger, greener concrete with biofuel byproducts 2Researchers building stronger, greener concrete with biofuel byproducts 3
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
KOR-1 (C-20)...
...
Biology Products: